Hanmi Pharmaceutical 1.8trillion-won technology transfer and details emerge on Hyundai Motor collaboration

![Hanmi Pharmaceutical 1.8trillion-won technology transfer and details emerge on Hyundai Motor collaboration/blog-images/gen-5874aea7-ed16-400b-bdc5-ed70f21fb445.jpg)

Hanmi Pharmaceutical 1.8announced that it had signed a technology transfer agreement worth trillion won. Following the news, its shares remained strong for a second day. Some securities firms were reported to have raised their target prices for Hanmi Pharmaceutical.

Hyundai Motor disclosed that it is at the stage of fleshing out its collaboration with Boston Dynamics. A report cited a case in which a target price of ten thousand won was set. The company said it was reviewing specific execution plans for the direction of the collaboration.100The company said it was reviewing specific execution plans for the direction of the collaboration.

The outlook for Hyundai Mobis’s actuator business was assessed as bright. In connection with this, some securities firms raised their target prices. The company said it is developing the actuator business as a core business within its electrification parts lineup.

A divergence emerged in vehicle sales results. 5That month, Hyundai Motor’s sales were sluggish due to parts shortages, while Kia performed well on the back of expanded sales of eco-friendly vehicles. The two companies continue to disclose parts supply conditions and the share of electric vehicle sales, respectively.

Marketing news from the financial industry also emerged. A securities firm launched a promotion offering shares of Samsung Electronics, Hyundai Motor, and Doosan Enerbility to new customers. The promotion terms and eligibility criteria can be found in the securities firm’s notice.